CONFIDENTIAL TREATMENT REQUESTED
Exhibit 10.46
CONFIDENTIAL TREATMENT REQUESTED
CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. INFORMATION THAT WAS OMITTED IN THE EDGAR VERSION HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK [***].
AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT | 1. CONTRACT ID CODE | PAGE OF PAGES | ||||||||
1 | 2 |
2. AMENDMENT/MODIFICATION NO. | 3. EFFECTIVE DATE | 4. REQUISITION/PURCHASE REQ. NO. | 5 PROJECT NO, (If applicable) | |||||||||
0001
| 10/15/2015 | |||||||||||
5. ISSUED BY | CODE | ASPR-BARDA | 7. ADMINISTERED BY (If other than Item 6) | ASPR-BARDA01 | ||||||||
ASPR - BARDA 200 Independence Ave., S.W. Room 640-G Washington DC 20201
|
ASPRBARDA 330 Independence Ave, SW, Rm G644 Washington DC 20201 | |||||||||||
8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP code
PFENEX, INC 1358378 FENEX BIOPHARMACEUTICALS, INC. 10790 ROSELLE ST SAN DIEGO CA 921211718 | 00 | 9A. AMENDMENT OF SOLICITATION NO.
| ||||||||||
9B. DATED (SEE ITEM 11)
| ||||||||||||
x | 10A. MODIFICATION OF CONTRACT/ORDER NO. | |||||||||||
HHSO100201500011C
| ||||||||||||
10B. DATED (SEE ITEM 13) | ||||||||||||
CODE 1358378
| FACILITY CODE
| 08/14/2015
|
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS | ||||
The above numbered solicitation is amended as set forth in Item 14. The hour end date specified for receipt of Offers is extended is not extended. Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods: (a) By completing Items 8 and 15, and returning copies of the amendment; (b) By acknowledging receipt of this Amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified. | ||||
12. ACCOUNTING AND APPROPRIATION. DATA (if required) | ||||
See Schedule | ||||
13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14. | ||||
CHECK ONE | A. | THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A. | ||
B. | THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b). | |||
x | ||||
C. | THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: | |||
D. | OTHER (Specify type of modification and authority) | |||
E. IMPORTANT: Contractor is not X is required to sign this document and return 1 copies to the issuing office.
| ||||
14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.) Tax ID Number: 27-1356759 DUNS Number:   ###-###-#### Pfenex - RPA563 and Px563L Advanced Development A. The purpose of this modification is to transfer material from contract # HHS0100201000045C (see inventory list) to contract #HHS0100201 500011C. The material is needed on contract # - 0011C to complete the advanced research and development of a next generation anthrax vaccine. The total cost of the contract and all terms and conditions remain unchanged. B. Update the Contracting Officer from Francine Hemphill to Wendell Conyers in sections Article F.2, Article G.1 and Article G.5.
Continued Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect. |
15A. NAME AND TITLE OF SIGNER (Type or print) | 16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print) | |||||
PATRICK LUCY | WENDELL CONYERS | |||||
15B. CONTRACTOR/OFFEROR | 15C. DATE SIGNED | 16B. UNITED STATES OF AMERICA | 16C. DATE SIGNED | |||
/s/ Patrick Lucy (Signature of person authorized to sign) |
21 Oct 15 |
/s/ Wendell Conyers (Signature of Contracting Officer) |
10-21-2015 |
NSN 7540-01-152-8070 | STANDARD FORM 30 (REV. 10-83) | |
Previous edition unusable | Prescribed by GSA | |
FAR (48 CFR) 53.243 |
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
CONTINUATION SHEET | REFERENCE NO. OF DOCUMENT BEING CONTINUED | PAGE | OF | |||
HHS0100201500011C/0001 | 2 | 2 |
NAME OF OFFEROR OR CONTRACTOR
| ||
PFENEX, INC 1358378 |
ITEM NO. (A) | SUPPLIES/SERVICES (B) | QUANTITY (C) | UNIT (D) | UNIT PRICE (E) | AMOUNT (F) | |||||
Discount Terms: NET 30P Period of Performance: 08/14/2015 to 08/09/2020
|
NSN 7540-01-152-8087 | OPTIONAL FORM 335 (4-85) | |||
Sponsored by GSA | ||||
FAR (48 CFR) 53.110 |
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Inventory [***]
item | Description | Concentration | Volume | Container | Lot # | Date of Manuf. | Storage | Amount | Inventory date | Storage location | ||||||||||||||||||||||||||||
[***] | [***] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | |||||||||||||||||||
[***] | [***] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | |||||||||||||||||||
[***] | [***] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | |||||||||||||||||||
[***] | [***] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | |||||||||||||||||||
[***] | [***] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | |||||||||||||||||||
[***] | [***] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | |||||||||||||||||||
[***] | [***] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | |||||||||||||||||||
[***] | [***] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | |||||||||||||||||||
[***] | [***] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] |
[***]
[***]
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Pfenex Confidential | Page 3 of 7 |
[***]
Sentry Item number | Description | Concentration | Volume | Container | Lot # | Date of Manuf. | Storage | # Vials | Inventory date | Storage location | ||||||||||||||||||||||||||||
[***] | [***] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | |||||||||||||||||||
[***] | [***] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | |||||||||||||||||||
[***] | [***] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | |||||||||||||||||||
[***] | [***] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | |||||||||||||||||||
[***] | [***] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | |||||||||||||||||||
[***] | [***] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] | [*** | ] |
[***]
[***]
[***]
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Pfenex Confidential | Page 4 of 7 |
[***]
Reagent/Materials Name | mrPA lot/DOM | Description | Amount left (units) | Storage Condition (ºC) | Date | |||||||||||
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] | ||||||||
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] | ||||||||
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] | ||||||||
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] | ||||||||
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] | ||||||||
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] |
[***]
[***]
Reagent/Materials Name | mrPA lot | Description | Amount left (units) | Storage Condition (°C) | Date | |||||||||||
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] | ||||||||
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] | ||||||||
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] | ||||||||
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] |
[***]
Reagent/Materials Name | Lot | Description | Amount left (units) | Storage Condition (°C) | Date | |||||||||||
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] | ||||||||
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] | ||||||||
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] |
[***]
Reagent/Materials Name | Source | Description | Amount left (units) | Storage Condition (ºC) | Date | |||||||||||
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] | ||||||||
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] | ||||||||
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] |
[***]
Reagent/Materials Name | Strain | Description | Amount left (units) | Storage Condition (°C) | Date | |||||||||||
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] | ||||||||
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] |
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Pfenex Confidential | Page 5 of 7 |
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] | ||||||||
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] | ||||||||
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] | ||||||||
Reagent/Materials Name | Description | Amount left (units) | Storage Condition (°C) | Date | ||||||||||||
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] | ||||||||
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] | ||||||||
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] |
[***]
Reagent/Materials Name | Description | Amount left (units) | Storage Condition (°C) | Date | ||||||||||||
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] | ||||||||
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] | ||||||||
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] | ||||||||
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] | ||||||||
[***] | [***] | [***] | [*** | ] | [*** | ] | [*** | ] |
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Pfenex Confidential | Page 6 of 7 |
ARTICLE F.2. DELIVERABLES
a. Summary of Contract Deliverables
Unless otherwise specified by the Contracting Officer, the deliverables identified in this SECTION F shall also be delivered electronically to the designated eRoom along with a concurrent email notification sent to the Contracting Officer, Contract Specialist, COR, and Alternate COR stating delivery has been made.
All paper/hardcopy documents/reports submitted under this contract shall be printed or copied, double-sided, on at least 30 percent post-consumer fiber paper, whenever practicable, in accordance with FAR 4.302(b). Hard copies of deliverables and reports furnished to the USG under the resultant Contract (including invoices) shall be addressed as follows:
HHS/ASPR/AMCG
ATTN: Wendell Conyers, Contracting Officer 330 Independence Avenue,
SW., Room G640 Washington, DC 20201
Email: ***@***
ARTICLE G.1. CONTRACTING OFFICER
The following Contracting Officer (CO) will represent the USG for the purpose of this contract:
Wendell Conyers
Contracting Officer
HHS/ASPR/AMCG
330 Independence Avenue, S.W. Room G644 Washington, D.C. 20201
((202) 205-8262
***@***
ARTICLE G.5. INVOICE/FINANCING REQUEST AND CONTRACT FINANCIAL REPORTING
Include Program Support Center (PSC) In Receipt of Invoices:
Documents shall be delivered electronically to the Contracting Officer (CO), the Contracting Specialist (CS), the Contracting Officers Representative (COR) and PSC. Unless otherwise specified by the Contracting Officer all deliverables and reports furnished to the Government under the resultant contract (including invoices) shall be addressed as follows:
Wendell Conyers Contracting Officer HHS/ASPR/AMCG 330 Independence Ave., S.W., Room G640 Washington, DC 20201 Email: ***@*** | Daniel Wolfe Contracting Officer Representative HHS/ASPR/BARDA 330 Independence Ave., S.W., Room G640 Washington, DC 20201 Email: ***@*** | ***@*** |
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Pfenex Confidential | Page 7 of 7 |